ZRMQ-22, a novel DYRK1A inhibitor, attenuates neuroinflammation and cognitive impairments in LPS-induced mice: a potential strategy for Alzheimer's disease
{{output}}
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by irreversible cognitive decline and memory loss. Targeting the kinase DYRK1A has emerged as a promising therapeutic strategy, as it plays a critical role in multiple key AD p... ...
